跳转至内容
Merck
CN
  • Enhanced nicotine self-administration and suppressed dopaminergic systems in a rat model of diabetes.

Enhanced nicotine self-administration and suppressed dopaminergic systems in a rat model of diabetes.

Addiction biology (2013-07-10)
Laura E O'Dell, Luis A Natividad, Joseph A Pipkin, Francisco Roman, Ivan Torres, Jesus Jurado, Oscar V Torres, Theodore C Friedman, John M Tenayuca, Arbi Nazarian
摘要

Patients with diabetes display a heightened propensity to use tobacco; however, it is unclear whether they experience enhanced rewarding effects of nicotine. Thus, this study examined the reinforcing effects of nicotine in a rodent model of diabetes involving administration of streptozotocin (STZ), a drug that is toxic to pancreatic insulin-producing cells. The first study compared STZ- and vehicle-treated rats that had 23-hour access to intravenous self-administration (IVSA) of nicotine or saline and concomitant access to food and water. In order to examine the contribution of dopamine to our behavioral effects, dopamine transporter (DAT), D1 and D2 receptor levels were compared in the nucleus accumbens (NAc) following 10 days of nicotine or saline IVSA. Dopamine levels in the NAc were also compared following nicotine administration. Lastly, nicotine metabolism and dose-dependent effects of nicotine IVSA were assessed. The results revealed that STZ-treated rats displayed enhanced nicotine intake and a robust increase in food and water intake relative to controls. Protein analysis revealed an increase in DAT and a decrease in D1 receptor levels in the NAc of STZ- versus vehicle-treated rats regardless of IVSA condition. STZ-treated rats also displayed suppressed NAc dopamine levels during baseline and in response to nicotine. STZ treatment did not alter our assessment of nicotine metabolism. Furthermore, STZ treatment increased nicotine IVSA in a dose-dependent manner. Our findings suggest that STZ-treatment increased the rewarding effects of nicotine. This suggests that strong reinforcing effects of nicotine may contribute to greater tobacco use in patients with diabetes.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
磷酸酶抑制剂混合物2, aqueous solution (dark coloration may develop upon storage, which does not affect the activity)
Sigma-Aldrich
磷酸酶抑制剂混合物 1, DMSO solution
Sigma-Aldrich
抗-多巴胺D2受体抗体, Chemicon®, from rabbit
Sigma-Aldrich
抗-多巴胺D1A受体抗体,克隆SG2-D1a, clone SG2-D1a, Chemicon®, from mouse